References,Sample size,Interventions,Main race,Female (%),Mean HAMA,Mean age (Year),Attrition rate (%),Sponsor,Follow-up time (weeks),Diagnosis criteria
"Khan et al., 2011",951,quetiapine: 50 mg/day,NA,NA,NA,NA,15.4,AstraZeneca Pharmaceuticals,10,dsm-iv-tr
"Khan et al., 2011",951,quetiapine: 150 mg/day,NA,NA,NA,NA,15.6,AstraZeneca Pharmaceuticals,10,dsm-iv-tr
"Khan et al., 2011",951,quetiapine: 300 mg/day,NA,NA,NA,NA,18.5,AstraZeneca Pharmaceuticals,10,dsm-iv-tr
"Khan et al., 2011",951,placebo,NA,NA,NA,NA,13.9,AstraZeneca Pharmaceuticals,10,dsm-iv-tr
